U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H33NO2
Molecular Weight 391.5467
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ABIRATERONE ACETATE

SMILES

CC(=O)O[C@@]1([H])CC[C@@]2(C)C(=CC[C@@]3([H])[C@]4([H])CC=C(c5cccnc5)[C@@]4(C)CC[C@@]32[H])C1

InChI

InChIKey=UVIQSJCZCSLXRZ-UBUQANBQSA-N
InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1

HIDE SMILES / InChI

Molecular Formula C26H33NO2
Molecular Weight 391.5467
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002321/WC500112860.pdf

Abiraterone acetate (trade name Zytiga) is a prodrug to the abiraterone, steroidal compound with antiandrogen activity and a 17 α-hydroxylase/C17,20-lyase (CYP17) inhibitor. It is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone acetate is converted in vivo to abiraterone which inhibits CYP17, enzyme expressed in testicular, adrenal, and prostatic tumor tissues and required for androgen biosynthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor.

CNS Activity

Curator's Comment:: Abiraterone was able to cross the blood brain barrier since 14C-abiraterone had been measured in the cerebellum, cerebrum, medulla and spinal cord.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
110.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZYTIGA

Approved Use

Indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Launch Date

1.30394882E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
226 ng/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
297 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12.5 ng/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
50.2 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
60.6 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
85.7 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
71.9 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
64.5 ng/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1173 ng × h/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1562 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
177 ng × h/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
315 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
315 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
330 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
365 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
461 ng × h/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.6 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18.2 h
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.2 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18.2 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.1 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17.7 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15.4 h
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Disc. AE: Cardiac failure, AST high...
Other AEs: Lymphopenia, Lymphopenia...
AEs leading to
discontinuation/dose reduction:
Cardiac failure (5 patients)
AST high (1%)
ALT high (1%)
Other AEs:
Lymphopenia (grade 1-2, 29.3%)
Lymphopenia (grade 3-4, 8.7%)
Hyperglycemia (grade 1-2, 50.5%)
Hyperglycemia (grade 3-4, 6.5%)
ALT high (grade 1-2, 35.9%)
ALT high (grade 3-4, 6.1%)
AST high (grade 1-2, 33.9%)
AST high (grade 3-4, 3.1%)
Hypernatremia (grade 1-2, 32.6%)
Hypernatremia (grade 3-4, 0.4%)
Hypokalemia (grade 1-2, 14.2%)
Hypokalemia (grade 3-4, 2.8%)
Cardiac failure (grade 3-4, 1.6%)
Cardiac failure (grade 5, 2 patients)
Sources:
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Other AEs: Fatigue, Fatigue...
Other AEs:
Fatigue (grade 1-2, 39%)
Fatigue (grade 3-4, 2.2%)
Edema peripheral (grade 1-2, 25%)
Pitting edema (grade 1-2, 25%)
Generalized edema (grade 1-2, 25%)
Pyrexia (grade 1-2, 8.7%)
Pyrexia (grade 3-4, 0.6%)
Arthritis (grade 1-2, 30%)
Arthralgia (grade 1-2, 30%)
Joint swelling (grade 1-2, 30%)
Joint stiffness (grade 1-2, 30%)
Groin pain (grade 1-2, 6.6%)
Constipation (grade 1-2, 23%)
Diarrhea (grade 1-2, 22%)
Dyspepsia (grade 1-2, 11%)
Hot flush (grade 1-2, 22%)
Hot flush (grade 3-4, 0.2%)
Hypertension (grade 1-2, 22%)
Hypertension (grade 3-4, 3.9%)
Cough (grade 1-2, 17%)
Dyspnea (grade 1-2, 12%)
Dyspnea (grade 3-4, 2.4%)
Insomnia (grade 1-2, 14%)
Insomnia (grade 3-4, 0.2%)
Contusion (grade 1-2, 13%)
Fall (grade 1-2, 5.9%)
Upper respiratory tract infection (grade 1-2, 13%)
Nasopharyngitis (grade 1-2, 8%)
Hematuria (grade 1-2, 10%)
Hematuria (grade 3-4, 1.3%)
Rash (grade 1-2, 8.1%)
Sources:
2000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 1 times / day
Sources: Page: p. 27
unhealthy
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Sex: M
Sources: Page: p. 27
AEs

AEs

AESignificanceDosePopulation
ALT high 1%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
AST high 1%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Cardiac failure 5 patients
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypokalemia grade 1-2, 14.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Lymphopenia grade 1-2, 29.3%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypernatremia grade 1-2, 32.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
AST high grade 1-2, 33.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
ALT high grade 1-2, 35.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hyperglycemia grade 1-2, 50.5%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypernatremia grade 3-4, 0.4%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Cardiac failure grade 3-4, 1.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypokalemia grade 3-4, 2.8%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
AST high grade 3-4, 3.1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
ALT high grade 3-4, 6.1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hyperglycemia grade 3-4, 6.5%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Lymphopenia grade 3-4, 8.7%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Cardiac failure grade 5, 2 patients
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hematuria grade 1-2, 10%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Dyspepsia grade 1-2, 11%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Dyspnea grade 1-2, 12%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Contusion grade 1-2, 13%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Upper respiratory tract infection grade 1-2, 13%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Insomnia grade 1-2, 14%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Cough grade 1-2, 17%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Diarrhea grade 1-2, 22%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hot flush grade 1-2, 22%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hypertension grade 1-2, 22%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Constipation grade 1-2, 23%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Edema peripheral grade 1-2, 25%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Generalized edema grade 1-2, 25%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Pitting edema grade 1-2, 25%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Arthralgia grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Arthritis grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Joint stiffness grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Joint swelling grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Fatigue grade 1-2, 39%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Fall grade 1-2, 5.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Groin pain grade 1-2, 6.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Nasopharyngitis grade 1-2, 8%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Rash grade 1-2, 8.1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Pyrexia grade 1-2, 8.7%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hot flush grade 3-4, 0.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Insomnia grade 3-4, 0.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Pyrexia grade 3-4, 0.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hematuria grade 3-4, 1.3%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Fatigue grade 3-4, 2.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Dyspnea grade 3-4, 2.4%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hypertension grade 3-4, 3.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
strong [Ki 0.16 uM]
yes (co-administration study)
Comment: The systemic exposure of dextromethorphan (CYP2D6 substrate) as assessed by the ratios of the geometric mean for Cmax and AUC, were approximately 2.8- and 2.9-fold higher, respectively, when dextromethorphan was co-administered with abiraterone acetate
Page: 8.0
strong [Ki 0.32 uM]
yes [IC50 10.8 uM]
yes [Ki 0.12 uM]
yes [Ki 0.39 uM]
yes [Ki 0.44 uM]
yes [Ki 11.4 uM]
yes [Ki 17.6 uM]
yes [Ki 29.8 uM]
yes [Ki 31.8 uM]
yes [Ki 46.3 uM]
yes [Ki 8.01 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer.
2010 Jul
Abiraterone acetate.
2011 Aug 1
[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
2012 Feb
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men.
2012 Jun
Differential response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal testis xenograft bioassay.
2014 Mar
Patents

Sample Use Guides

1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily. Zytiga must be taken on an empty stomach. No food should be consumed for at least two hours before the dose of Zytiga is taken and for at least one hour after the dose of Zytiga is taken. For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the Zytiga starting dose to 250 mg once daily. For patients who develop hepatotoxicity during treatment, hold Zytiga until recovery. Retreatment may be initiated at a reduced dose. Zytiga should be discontinued if patients develop severe hepatotoxicity.
Route of Administration: Oral
Abiraterone acetate (CB 7630) inhibits CYP17 with an IC50 of 110 nM in human testicular microsomes. In Caco-2 cell monolayers abiraterone acetate had a low apparent permeability and was not substrate of P-glycoprotein (P-gp). Abiraterone acetate inhibited P-gp significantly at high concentrations with a 50 % inhibitory concentration (IC50) of 10.8 uM however as abiraterone acetate is rapidly converted to abiraterone, no systemic inhibition of P-gp is expected.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:06:25 UTC 2021
Edited
by admin
on Fri Jun 25 22:06:25 UTC 2021
Record UNII
EM5OCB9YJ6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ABIRATERONE ACETATE
DASH   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
ANDROSTA-5,16-DIEN-3-OL, 17-(3-PYRIDINYL)-, ACETATE (ESTER), (3.BETA.)-
Common Name English
ABIRATERONE ACETATE [MI]
Common Name English
NSC-748121
Code English
YONSA
Brand Name English
ABIRATERONE ACETATE [WHO-DD]
Common Name English
ABIRATERONE ACETATE [MART.]
Common Name English
ABIRATERONE ACETATE [USP-RS]
Common Name English
ZYTIGA
Brand Name English
NSC-749227
Code English
ABIRATERONE ACETATE [USP MONOGRAPH]
Common Name English
CB7630
Code English
17-(PYRIDIN-3-YL)ANDROSTA-5,16-DIEN-3.BETA.-YL ACETATE
Systematic Name English
CB-7630
Code English
ABIRATERONE (AS ACETATE)
Common Name English
JNJ-212082
Common Name English
ABIRATERONE ACETATE [VANDF]
Common Name English
ABIRATERONE ACETATE [ORANGE BOOK]
Common Name English
ABIRATERONE ACETATE [USAN]
Common Name English
ABIRATERONE ACETATE [JAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS ZYTIGA (AUTHORIZED: PROSTATIC NEOPLASMS)
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
NCI_THESAURUS C147923
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
Code System Code Type Description
DRUG BANK
DBSALT001173
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
DRUG CENTRAL
4176
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
EPA CompTox
154229-18-2
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
NCI_THESAURUS
C68845
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
RXCUI
1100071
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1000818
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY USP-RS
EVMPD
SUB31647
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
PUBCHEM
9821849
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL271227
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
MERCK INDEX
M1279
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY Merck Index
CAS
154229-18-2
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
FDA UNII
EM5OCB9YJ6
Created by admin on Fri Jun 25 22:06:26 UTC 2021 , Edited by admin on Fri Jun 25 22:06:26 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> NON-SUBSTRATE
TRANSPORTER -> INHIBITOR
Abiraterone acetate inhibits Pgp significantly, with an IC50 of 10.8 ?M in vitro.
IC50
TARGET -> INHIBITOR
NEEDS TO BE ACTIVATE TO ABIRATERONE
EXCRETED UNCHANGED
FECAL
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC